Cargando…
Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2020 and coronavirus disease 19 (COVID-19) was later announced as pandemic by the World Health Organization (WHO). Since then, several studies have been conducted on the prevention and treatment of COVI...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Masson SAS.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962551/ https://www.ncbi.nlm.nih.gov/pubmed/33774315 http://dx.doi.org/10.1016/j.biopha.2021.111518 |
_version_ | 1783665492624408576 |
---|---|
author | Mirtaleb, Mona Sadat Mirtaleb, Amir Hossein Nosrati, Hassan Heshmatnia, Jalal Falak, Reza Zolfaghari Emameh, Reza |
author_facet | Mirtaleb, Mona Sadat Mirtaleb, Amir Hossein Nosrati, Hassan Heshmatnia, Jalal Falak, Reza Zolfaghari Emameh, Reza |
author_sort | Mirtaleb, Mona Sadat |
collection | PubMed |
description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2020 and coronavirus disease 19 (COVID-19) was later announced as pandemic by the World Health Organization (WHO). Since then, several studies have been conducted on the prevention and treatment of COVID-19 by potential vaccines and drugs. Although, the governments and global population have been attracted by some vaccine production projects, the presence of SARS-CoV-2-specific antiviral drugs would be an urge necessity in parallel with the efficient preventive vaccines. Various nonspecific drugs produced previously against other bacterial, viral, and parasite infections were recently evaluated for treating patients with COVID-19. In addition to therapeutic properties of these anti-COVID-19 compounds, some adverse effects were observed in different human organs as well. Not only several attentions were paid to antiviral therapy and treatment of COVID-19, but also nanomedicine, immunotherapy, and cell therapy were conducted against this viral infection. In this review study, we planned to introduce the present and potential future treatment strategies against COVID-19 and define the advantages and disadvantages of each treatment strategy. |
format | Online Article Text |
id | pubmed-7962551 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Authors. Published by Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79625512021-03-16 Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy Mirtaleb, Mona Sadat Mirtaleb, Amir Hossein Nosrati, Hassan Heshmatnia, Jalal Falak, Reza Zolfaghari Emameh, Reza Biomed Pharmacother Review Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2020 and coronavirus disease 19 (COVID-19) was later announced as pandemic by the World Health Organization (WHO). Since then, several studies have been conducted on the prevention and treatment of COVID-19 by potential vaccines and drugs. Although, the governments and global population have been attracted by some vaccine production projects, the presence of SARS-CoV-2-specific antiviral drugs would be an urge necessity in parallel with the efficient preventive vaccines. Various nonspecific drugs produced previously against other bacterial, viral, and parasite infections were recently evaluated for treating patients with COVID-19. In addition to therapeutic properties of these anti-COVID-19 compounds, some adverse effects were observed in different human organs as well. Not only several attentions were paid to antiviral therapy and treatment of COVID-19, but also nanomedicine, immunotherapy, and cell therapy were conducted against this viral infection. In this review study, we planned to introduce the present and potential future treatment strategies against COVID-19 and define the advantages and disadvantages of each treatment strategy. The Authors. Published by Elsevier Masson SAS. 2021-06 2021-03-16 /pmc/articles/PMC7962551/ /pubmed/33774315 http://dx.doi.org/10.1016/j.biopha.2021.111518 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Mirtaleb, Mona Sadat Mirtaleb, Amir Hossein Nosrati, Hassan Heshmatnia, Jalal Falak, Reza Zolfaghari Emameh, Reza Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy |
title | Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy |
title_full | Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy |
title_fullStr | Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy |
title_full_unstemmed | Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy |
title_short | Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy |
title_sort | potential therapeutic agents to covid-19: an update review on antiviral therapy, immunotherapy, and cell therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962551/ https://www.ncbi.nlm.nih.gov/pubmed/33774315 http://dx.doi.org/10.1016/j.biopha.2021.111518 |
work_keys_str_mv | AT mirtalebmonasadat potentialtherapeuticagentstocovid19anupdatereviewonantiviraltherapyimmunotherapyandcelltherapy AT mirtalebamirhossein potentialtherapeuticagentstocovid19anupdatereviewonantiviraltherapyimmunotherapyandcelltherapy AT nosratihassan potentialtherapeuticagentstocovid19anupdatereviewonantiviraltherapyimmunotherapyandcelltherapy AT heshmatniajalal potentialtherapeuticagentstocovid19anupdatereviewonantiviraltherapyimmunotherapyandcelltherapy AT falakreza potentialtherapeuticagentstocovid19anupdatereviewonantiviraltherapyimmunotherapyandcelltherapy AT zolfaghariemamehreza potentialtherapeuticagentstocovid19anupdatereviewonantiviraltherapyimmunotherapyandcelltherapy |